Work

Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study

Year: 2026

Type: article

Abstract: The treatment landscape for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved over the last decade. Clinical trials have shown that treatment intensification in this setting, comprising chemotherapy and/or androgen-receptor pathway inhibitors, has shown benefit in delaying tumour progression and improving overall survival [1, 2]. More recently, the addition of localised prostate radiotherapy has also shown significant improvement in overall survival for men with low-burden metastatic disease, a finding supported by a recent large-scale meta-analysis [3].

Source: British Journal of Urology

DOI: 10.1111/bju.70432

Authors: Arjun Nathan, Matthew G. Parry, Emily Mayne, Adrian Cook, Justin Liu, Raghav Varma, Will Cuningham, Joanna Dodkins, Marina Parry, Julie Nossiter, Ajay Aggarwal, Jan van der Meulen, Alison Tree, Noel Clarke

Institutions: Royal College of Surgeons of England, London School of Hygiene & Tropical Medicine, University College London, Guy's and St Thomas' NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, University of Manchester, Cancer Research UK Manchester Institute, The Christie Hospital, The Christie NHS Foundation Trust

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,770

Funders: Royal Marsden NHS Foundation Trust, Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, Urology Foundation

Awards: Malignant Ureteric Obstruction in Prostate Cancer: a National Population-based Study, G2946636271, G4785333599, G5919881315, G5944187931, G6203797394, G995337982

OpenAlex ID: W7221059046

FWCI:

Cites: 8

Cited by:

Related to: 10